Shenyang Xingqi Pharmaceutical Co., Ltd. Class A

Shenyang Xingqi Pharmaceutical Co., Ltd. Class A

SSZSE:300573
34.04
CNY
+0.80
(+2.41%)
2.24EPS
16.19P/E
12.93BMarket Cap
Apr 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.92
1.07
1.22
1.41
1.12
1.35
1.71
2.14
3.17
3.57
4.16
5.47
6.94
7.87
Basic EPS, GAAP
0.19
0.13
0.09
0.23
0.12
0.04
0.11
0.27
0.6
0.61
0.68
0.95
1.95
2.25
Free Cash Flow per Basic Share
-0.52
-0.29
0.07
0.1
0.01
- -
0.01
0.04
0.65
-0.04
0.16
0.61
1.35
- -
Dividend per Share
0.02
0.04
0.04
0.03
0.04
0.07
0.08
0.05
0.15
0.23
0.51
1.31
0.98
0.99
Book Value per Share
1.41
1.54
1.63
1.64
1.73
1.66
1.73
2.08
4.1
4.41
4.77
4.48
5.54
6.29
Tangible Book Value per Share
1.3
1.43
1.52
1.56
1.65
1.59
1.66
1.94
3.88
4.06
4.24
3.93
4.91
5.7
Basic Weighted Avg Shares
238
237
236
240
320
320
317
321
324
350
353
355
357
356
Sales/Revenue/Turnover
219
255
287
339
360
431
542
689
1,028
1,250
1,468
1,943
2,473
2,807
Operating Margin (%)
24.19
12.97
12.53
17.27
14.14
4
8.65
16.84
24.32
19.76
19.24
22.37
34.12
34.07
Depreciation Expense
11
33
38
38
37
36
41
46
67
74
89
103
113
- -
Net Income, GAAP
46
31
22
54
39
14
36
88
195
212
240
338
696
802
Effective Tax Rate (%)
16.73
17.53
16.41
15.82
16.14
19.34
17.61
8.86
14.14
9.43
9.42
14.42
13.05
12.68
Profit Margin (%)
21.08
12.18
7.65
16.01
10.95
3.17
6.62
12.77
18.94
16.94
16.36
17.4
28.14
28.58
Working Capital
-7
-71
-61
76
102
86
61
71
718
713
645
368
430
537
LT Debt
60
56
20
- -
- -
- -
- -
30
7
7
2
9
4
98
Total Equity
337
368
390
521
553
555
575
694
1,344
1,552
1,690
1,593
1,978
2,232
Return on Invested Capital (%)
10.51
2.99
3.45
8.5
6.22
1.53
4.87
13
18.7
14.92
15.03
20.18
36.15
- -
Return on Capital (%)
11.47
8.14
6.21
10.64
6.97
3.44
7.24
11.9
16.35
14.07
14.47
19.17
36.17
- -
Return on Common Equity (%)
14.69
8.8
5.8
11.92
7.36
2.49
6.44
14.07
19.21
14.62
14.81
20.59
38.97
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
77
56
7
LT Borrowings
- -
- -
88
LT Finance Leases
3
3
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
357
357
355
Market Capitalization
16,215
14,564
12,930

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,133
1,014
1,141
Cash, Cash Equivalents & STI
574
466
538
Accounts Receivable, Net
273
285
326
Inventories
215
207
201
Total Current Liabilities
507
519
604
Payables & Accruals
- -
- -
- -
ST Debt
77
56
7
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.1%
27.29%
24.16%
Free Cash Flow
83.42%
238.31%
121.22%
Net Income, GAAP
65.22%
58.02%
105.84%
Sales/Revenue/Turnover
24.46%
29.59%
27.24%
Total Cash Common Dividend
62.92%
103.99%
-24.75%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
350
542
547
504
1,943
2025
536
627
- -
569
2,473
2026
683
718
837
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.38
0.34
0.13
0.95
2025
0.41
0.53
- -
0.27
1.95
2026
0.58
0.63
0.77
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1.06
0.01
0.25
1.31
2025
- -
0.5
- -
- -
0.98
2026
- -
0.69
0.3
- -
- -

Company Description

CEO
E Gao
Full Time Employees
2,396
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building B, Enterprise Plaza Shenyang LI China 110016
IPO Date
Dec 7, 2016
Website
sinqi.com
Business
Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) is a high-tech enterprise specializing in the research, development, production, and sale of ophthalmic drugs in China. Founded in 1977 and headquartered in Shenyang, Liaoning Province, the company offers a broad portfolio of eye care products including myopia prevention and control medications such as Xingqi Meoupin atropine sulfate eye drops for delaying myopia progression in children aged 6-12; dry eye treatments like Zirun cyclosporine eye drops, Sugaojie calf blood deproteinized extract eye gel and drops, Ziyang vitamin A palmitate eye gel, Yingrun hydroxypropyl methylcellulose eye drops, Aoshiming and Aierning sodium hyaluronate eye drops; ophthalmic anti-infective drugs such as Dikelo levofloxacin and ofloxacin eye drops and ointment, Dinuo lysostaphin eye drops, Diyou gatifloxacin eye gel; anti-inflammatory products including Difei diclofenac sodium eye drops; mydriatic and cycloplegic agents like Zhuobian compound tropicamide eye drops and Disan atropine sulfate eye gel; miotic and anti-glaucoma drugs; and other offerings such as Shike compound electrolyte intraocular irrigation solution, along with ancillary services in ophthalmology hospitals, optometry, glasses, health foods, and medical devices. The company operates primarily in the People's Republic of China through an extensive distribution network of direct sales and pharmaceutical partnerships, targeting treatments for myopia, dry eye, infections, inflammation, and corneal conditions. In recent developments, Shenyang Xingqi reported strong first-half 2025 revenue growth of 30.4% to RMB 1.163 billion and net profit up 97.8% to RMB 335 million driven by expanded sales of low-concentration atropine products; announced expectations for CNY 850 million in funding as of May 2025; approved a 2024 final cash dividend of 10 yuan per 10 shares payable in May 2025; participated in the 2025 Gusu Dialogue on pharmaceutical packaging innovation in August 2025; and advanced its new drug pipeline while enhancing quality management initiatives including a quality season press release.